Mathew Joseph, Bansod Yogesh Kisan, Yadav Nishant, Murugan Janesh, Reddy Kovvuru Bhaskar, Kazi Mufaddal, DeSouza Ashwin, Saklani Avanish
Department of GI Surgical Oncology and Minimal Access Surgery, HealthCare Global Enterprises Ltd. (HCG), Bangalore, India.
Division of Colorectal Oncology, Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India.
Cancer Rep (Hoboken). 2025 Mar;8(3):e70174. doi: 10.1002/cnr2.70174.
Robotic surgery has been associated with superior short-term outcomes in patients undergoing total mesorectal excision (TME) for organ-confined rectal cancer. However, whether this approach offers an additional benefit over laparoscopy when performing lateral pelvic lymph node dissection (LPLND) with TME or extended TME (e-TME) in locally advanced rectal cancer (LARC) is not known.
This study was conducted to evaluate the outcomes of robotic and laparoscopic LPLND in patients with lateral pelvic node-positive LARC with reference to intraoperative safety, postoperative morbidity, pathological indices including nodal yield and node positivity rates, lateral pelvic recurrence rates, and short term event-free and overall survival.
In this retrospective single-center study, consecutive patients with non-metastatic histologically proven LARC and clinically significant lateral pelvic lymphadenopathy who had undergone laparoscopic or robotic LPLND with TME or e-TME between 2014 and 2023 were included, all procedures having been performed by minimal-access colorectal surgeons who were beyond the learning curve for either surgical approach. Of the 115 patients evaluated, 98.3% received neoadjuvant chemoradiotherapy, following which 27 (23.5%) underwent robotic and 88 (76.5%) laparoscopic LPLND with TME or e-TME. The baseline clinicodemographic features, treatment-related characteristics, and proportion of patients undergoing extended resections for persistent circumferential resection margin-positive rectal cancer (22.7% vs. 18.5%, respectively) were statistically similar in both groups. When comparing robotic with laparoscopic resections, no significant difference was observed in intraoperative parameters including procedure-associated blood loss (median 250 mL vs. 400 mL) and on-table adverse events or conversion rates (none in either group), postoperative outcomes comprising clinically significant early (14.8% vs. 9.1%), intermediate (5.3% vs. 1.9%) and late (5.3% vs. 2.0%) surgical morbidity, re-exploration rates (7.4% vs. 3.4%) and duration of hospital stay (median 6 days in both groups), or the pathological quality indices of margin involvement (7.4% vs. 2.3%), nodal yield (median 4 vs. 7 nodes) and lateral node positivity (22.2% vs. 26.1%), respectively. At a median 11 months follow-up, oncological outcomes in terms of lateral pelvic recurrence rates (3.7% vs. 4.5%), 2-year event-free survival (78.7% vs. 79.3%) and 2-year overall survival (83.1% vs. 93.8%) were also comparable.
Surgical competence in laparoscopy may offset the potential benefits extended by robotic platforms. In a high-volume setup with experienced minimal-access surgeons, the clinical, pathological, and short-term oncological outcomes associated with both approaches may be considered equivalent.
对于接受全直肠系膜切除术(TME)的局限性直肠癌患者,机器人手术与更好的短期预后相关。然而,在局部晚期直肠癌(LARC)中,当进行TME或扩大TME(e-TME)联合侧方盆腔淋巴结清扫(LPLND)时,这种方法是否比腹腔镜手术具有额外的优势尚不清楚。
本研究旨在评估机器人辅助和腹腔镜LPLND治疗侧方盆腔淋巴结阳性LARC患者的预后,参考术中安全性、术后发病率、包括淋巴结获取量和淋巴结阳性率在内的病理指标、侧方盆腔复发率以及短期无事件生存率和总生存率。
在这项回顾性单中心研究中,纳入了2014年至2023年间连续接受腹腔镜或机器人辅助LPLND联合TME或e-TME治疗的非转移性组织学确诊LARC且伴有临床显著侧方盆腔淋巴结肿大的患者,所有手术均由经验丰富的微创结直肠外科医生进行,他们已超越两种手术方式的学习曲线。在评估的115例患者中,98.3%接受了新辅助放化疗,之后27例(23.5%)接受了机器人辅助LPLND联合TME或e-TME,88例(76.5%)接受了腹腔镜LPLND联合TME或e-TME。两组患者的基线临床人口统计学特征、治疗相关特征以及因环周切缘阳性直肠癌进行扩大切除的患者比例(分别为22.7%和18.5%)在统计学上相似。比较机器人辅助手术与腹腔镜手术时,术中参数包括手术相关失血量(中位数250 mL对400 mL)、术中不良事件或中转率(两组均无)、术后结果包括具有临床意义的早期(14.8%对9.1%)、中期(5.3%对1.9%)和晚期(5.3%对2.0%)手术发病率、再次手术率(7.4%对3.4%)和住院时间(两组中位数均为6天),或切缘受累(7.4%对2.3%)、淋巴结获取量(中位数分别为4个对7个)和侧方淋巴结阳性率(22.2%对26.1%)的病理质量指标均无显著差异。在中位随访11个月时,侧方盆腔复发率(3.7%对4.5%)、2年无事件生存率(78.7%对79.3%)和2年总生存率(83.1%对93.8%)等肿瘤学结果也相当。
腹腔镜手术的技术能力可能抵消机器人平台带来的潜在优势。在由经验丰富的微创外科医生进行大量手术时,两种手术方式的临床、病理和短期肿瘤学结果可被视为相当。